Analysts Set Expectations for HealthEquity Q4 Earnings

Key Points

• Barrington Research has revised its Q4 2026 earnings per share forecast for HealthEquity down to $0.76, slightly below the previous estimate of $0.78, while maintaining an "Outperform" rating and a $125.00 price target.
• Several analysts have raised their target prices for HealthEquity, with Jefferies Financial Group setting a new target of $134.00, indicating a generally positive outlook for the stock.
• HealthEquity's recent quarterly earnings report exceeded expectations, posting $0.97 earnings per share against a consensus estimate of $0.81, alongside a revenue of $330.80 million.

HealthEquity, Inc. (NASDAQ:HQY - Free Report) - Stock analysts at Barrington Research lowered their Q4 2026 earnings per share estimates for HealthEquity in a research note issued to investors on Wednesday, September 3rd. Barrington Research analyst A. Paris now forecasts that the company will post earnings of $0.76 per share for the quarter, down from their previous forecast of $0.78. Barrington Research currently has a "Outperform" rating and a $125.00 price target on the stock. The consensus estimate for HealthEquity's current full-year earnings is $2.32 per share.

Other equities research analysts also recently issued reports about the company. Jefferies Financial Group boosted their target price on HealthEquity from $130.00 to $134.00 and gave the stock a "buy" rating in a report on Wednesday. JMP Securities boosted their target price on HealthEquity from $110.00 to $117.00 and gave the stock a "market outperform" rating in a report on Wednesday, June 4th. JPMorgan Chase & Co. boosted their target price on HealthEquity from $125.00 to $126.00 and gave the stock an "overweight" rating in a report on Wednesday. Deutsche Bank Aktiengesellschaft boosted their target price on HealthEquity from $98.00 to $115.00 and gave the stock a "buy" rating in a report on Thursday, June 5th. Finally, Bank of America boosted their target price on HealthEquity from $110.00 to $125.00 and gave the stock a "buy" rating in a report on Wednesday, June 4th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $119.77.

HealthEquity Trading Up 2.3%

NASDAQ HQY opened at $97.70 on Friday. The company has a quick ratio of 4.06, a current ratio of 4.23 and a debt-to-equity ratio of 0.47. The stock's 50 day moving average is $94.64 and its 200 day moving average is $95.26. HealthEquity has a twelve month low of $74.07 and a twelve month high of $116.65. The firm has a market capitalization of $8.42 billion, a PE ratio of 59.21, a P/E/G ratio of 1.42 and a beta of 0.50.

HealthEquity (NASDAQ:HQY - Get Free Report) last released its quarterly earnings results on Tuesday, June 3rd. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.16. HealthEquity had a return on equity of 12.04% and a net margin of 11.49%.The company had revenue of $330.80 million for the quarter, compared to analyst estimates of $322.25 million. During the same period in the previous year, the company posted $0.80 earnings per share.

Institutional Investors Weigh In On HealthEquity

Large investors have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC grew its stake in shares of HealthEquity by 24.7% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 6,380 shares of the company's stock valued at $564,000 after purchasing an additional 1,265 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of HealthEquity by 7,983.6% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,655 shares of the company's stock valued at $2,179,000 after purchasing an additional 24,350 shares during the period. GAMMA Investing LLC grew its stake in shares of HealthEquity by 25.9% during the 1st quarter. GAMMA Investing LLC now owns 1,571 shares of the company's stock valued at $139,000 after purchasing an additional 323 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of HealthEquity by 995.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 639,345 shares of the company's stock valued at $56,500,000 after purchasing an additional 580,988 shares during the period. Finally, WCM Investment Management LLC bought a new stake in shares of HealthEquity during the 1st quarter valued at about $20,230,000. 99.55% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Michael Henry Fiore sold 1,794 shares of the company's stock in a transaction on Monday, July 7th. The stock was sold at an average price of $101.73, for a total transaction of $182,503.62. Following the transaction, the executive vice president directly owned 53,225 shares of the company's stock, valued at $5,414,579.25. This represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.50% of the stock is currently owned by insiders.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.